Visions Magazine 01 - Bausch + Lomb | See Better. Live Better.

B+L Newsletter
26/3/08
11:07
Page 1001
Spring 08/Issue 01
B&L is saving
sight in Africa
A clear vision
of the future
The truth about
corneal staining
Zyoptix® leads
the way in
laser correction
B+L Newsletter
26/3/08
11:07
Page 02
02
Dear Colleagues
The last 6 months has been a very exciting
time at Bausch & Lomb. We have entered a
new era with new owners, a new CEO and a
new acquisition. To further strengthen our
commitment to you, I would like to introduce
the first Bausch & Lomb UK quarterly magazine,
written in conjunction with professionals in the
field of ophthalmology and optometry.
communications, enabling us to provide you with
quicker and better informed responses, linked
to our goal of providing you with an enhanced
customer experience. You can read more about
our customer service teams, and our plans to
ensure that we continue to offer you a world
class and continuously improving level of
service, in the B&L in focus section.
Our focus for 2008 is to ensure that we earn
and retain your trust as a business partner,
through offering comprehensive and holistic
support for all your business needs. Professional
education is a key theme for us this year,
and a list of our extensive range of courses
and symposiums can be found in the
Education section.
This year we also plan to increase our focus on
charitable support, by concentrating our efforts
with 3 eye related charities. These are Optometry
Giving Sight (where we are a Gold level UK
sponsor), British Blind Sport and Sightsavers
International. We believe that the incredible
difference these charities make to people's lives is
completely aligned to our own mission of
"Perfecting Vision and Enhancing Life". We are
proud to support this wonderful work. Read more
about our work with Sightsavers and how 72 year
old Tabitha from Zambia had her sight restored.
With a strong and supportive new owner in
Warburg Pincus, we are now even better
positioned to invest in innovation and advance
our leadership position in the eye health
industry. Our recent acquisition of eyeonics
is a visible sign of our commitment to deliver
innovative products to eye care professionals
and patients worldwide. The crystalens IOL
will further strengthen our cataract portfolio,
complementing other recently introduced
offerings such as the Stellaris™ Vision
Enhancement System and the Akreos® MI-60
Micro Incision IOL.
This inaugural edition of “Visions” magazine
contains a wide range of articles that we hope
you will find both interesting and informative,
and we would certainly welcome your ideas
regarding future content. Please send all
comments, suggestions and requests for further
information to the editor, Jill Collishaw, at
[email protected]
Best regards
At our UK Headquarters in Kingston-uponThames, we have recently redesigned the office
to allow all of our different business functions,
such as Marketing, Customer Service and
Finance, to work together in a dynamic
open-plan environment. This has improved
Gareth Steer, General Manager UK,
Nordics, Netherlands
“Our focus for 2008
is to ensure that
we earn and retain
your trust as
a business partner”
Inside this issue at a glance...
NEW PRODUCTS
HEALTH
What’s new for
Spring 2008
Latest stories &
B&L teams up
with Sightsavers
SCIENCE &
TECHNOLOGY
Leading the way
in innovation
EDUCATION
B&L IN FOCUS
Professional
education is
a key theme
Spotlight on
Customer
Services
B+L Newsletter
26/3/08
11:07
Page 03
NEW PRODUCTS
03
New Products...
W
NE
Lotemax®▼the new generation
ester steroid
Lotemax® (loteprednol etabonate 0.5%) is a new antiinflammatory corticosteroid eye drop for the treatment
of post-operative inflammation, due to become
available in the UK by April 2008.
Upgrade your patients to High
Definition Vision*
Crisp, sharp vision
Advanced aspheric optics reduce spherical
aberration and help promote crisp vision,
especially in low-level light conditions.
Lotemax® is a revolutionary new steroid that has
been specifically engineered for ophthalmic use.
It has a unique, site specific mechanism of action
which combines high anti-inflammatory efficacy
with improved safety, compared with other steroids
(Am. J. Ophthalmol., 1999).
Outstanding all-day comfort
Reduced mass design and proven hilafilcon B
high water content material combine to provide a
wettable surface and comfort throughout the day.
Easy handling
The hilafilcon B polymer enhances the tensile
property of the lens to reduce tearing, even by
first time users, and the new ergonomic blister
pack has been designed for smooth lens removal.
Loteprednol Etabonate US Uveitis Study Group.
Am. J. Ophthalmol.1999 May;127(5):537-44.
Prescribing Information
Lotemax® (0.5% loteprednol etabonate) Abbreviated Prescribing Information UK
(Please refer to full Summary of Product Characteristics when Prescribing)
Presentation: The suspension contains 0.5% loteprednol etabonate (5mg/ml). Each drop contains 0.19 mg
loteprednol etabonate. Uses: Treatment of post-operative inflammation following surgery. Dosage and
administration: Ocular: Adults and elderly One to two drops four times daily beginning 24 hours after surgery
and continuing throughout the post-operative period.The duration of treatment should NOT exceed 2 weeks.
Children and adolescents: contraindicated. Contraindications: viral diseases of the cornea and conjunctiva
including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial
infection of the eye and fungal diseases of ocular structures; untreated purulent acute infections, 'red eye'
with unknown diagnosis and infection caused by amoeba. Hypersensitivity to the active substance, to any of
the excipients, and to other corticosteroids. Precautions: Prolonged use of corticosteroids may result in ocular
hypertension or glaucoma, defects in visual acuity and fields of vision, and in posterior subcapsular cataract
formation. Steroids should be used with caution in the presence of glaucoma. Prolonged use of corticosteroids
may suppress the host response and may increase the possibility of secondary ocular infections. In those
diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of
topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing
infection. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb
formation. Long term treating with corticosteroids can cause fungal disease. Fungal disease should be
considered in the differential diagnosis when a corneal ulcer persists. Contains benzalkonium chloride which
may cause eye irritation. In general patients should not wear contact lenses after cataract surgery, unless
contact lens wearing is medically indicated. Contact with soft contact lenses should be avoided. Known to
discolour soft contact lenses. If signs and symptoms fail to improve after two days, the patient should be
re-evaluated. If this product is used for 10 days or longer, intraocular pressure should be monitored.
Interactions: the low potential of ocular loteprednol etabonate eye drops to increase the intraocular pressure
may be adversely affected by systemically administered medicinal products with anticholinergic activity.
SofLens® Daily Disposable
In patients receiving concomitant ocular hypotensive therapy, the addition of loteprednol etabonate may
increase intraocular pressure and decrease the apparent ocular hypotensive effect of these medicinal
products. Concurrent administration of cycloplegics may increase the risk of raised intraocular pressure.
Side effects: Reactions associated with ophthalmic steroids include elevated intraocular pressure in steroid
responsive patients, which may be associated with optic nerve damage, visual acuity and field defects,
posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes
simplex, and perforation of the globe where there is thinning of the cornea or sclera. Side-effects during
clinical trials included the following: corneal defect, eye discharge, ocular discomfort, dry eye, epiphora,
foreign body sensation in eyes, conjunctival hyperaemia and ocular itching, abnormal vision, blurring of
vision, chemosis,conjunctivitis, conjunctival hyperaemia, iritis, eye irritation, eye pain, conjunctival papillae,
photophobia, uveitis. Instillation site burning. Keratoconjunctivitis. Some of these events were similar to the
underlying ocular disease being studied, such as headache, migraine, taste perversion, dizziness,
paresthesia, asthenia, chest pain, chills, fever and pain, thoracic and mediastinal disorders, rhinitis, cough,
infections and infestations, pharyngitis, urinary tract infection and urethritis. Face oedema, urticaria, rash,
dry skin and eczema. Diarrhoea, nausea and vomiting, weight gain, tinnitus, neoplasms benign, malignant
and unspecified (incl cycts and polyps). Breast neoplasm, twitching, nervousness, rise in IOP. Use in
pregnancy and lactation:contraindicated. Overdosage: Acute overdosage is unlikely to occur via the
ophthalmic route. Basic NHS price: £4.95 Legal Category: POM Product Licence number:
PL17947/0001.Product Licence Holder:Bausch & Lomb GmbH,Brunsbütteler Damm 165-173, 13581 Berlin,
Germany. Date of Preparation: January 2006
Further Information is available from: Bausch & Lomb UK Ltd 106-114 London Road,
Kingston-Upon-Thames, KT2 6QJ. Tel: 01748 828864.
Adverse events should be reported via the Yellow Card Scheme. Information about the adverse event
reporting via this scheme can be found at www.yellowcard.gov.uk. Adverse events may also be
reported to Bausch & Lomb UK Ltd on 01748 828864.
Available April 2008
Stellaris™ Vision
Enhancement System
The new Bausch & Lomb Micro Incision Cataract
Surgery (MICS*) platform is now complete with the
introduction of the Stellaris™ Vision Enhancement
System. Designed by surgeons for surgeons for
exceptional safety, efficiency and ease of use.
*SofLens® One Day will be discontinued on 1st April
2008. Bausch & Lomb will cease all orders for
SofLens® One Day and has replaced the lens with its
latest generation daily disposable contact lens –
SofLens® daily disposable. SofLens® daily disposable
lenses are an easy direct upgrade from SofLens® One
Day with no need for additional chair time.
*MICS is a trademark of Bausch & Lomb
ReNu® MPS™ Flight Pack
Contact lens wearers can now take a special
ReNu® MPS™ Flight Pack on board
Due to increased security guidelines the carry-on
allowance for liquids has been severely restricted.
The new ReNu® MPS™ special Flight Pack
complies with the latest flight regulations as well
as the correct lens care regimen. The new ReNu®
MPS™ Flight Pack contains two 60ml bottles of
ReNu® MPS™ solution, two lens cases, a care
instruction leaflet and an official plastic zip-bag
for carry-on liquids.
ReNu® MPS™ Flight Pack trade price is £2.49.
RRP £4.95
Lotemax is a registered trademark, and MICS is a trademark, of Bausch & Lomb Incorporated.
B+L Newsletter
26/3/08
11:07
Page 04
HEALTH
04
A clear vision of the future
Professor Andrew Lotery, Professor of Ophthalmology, at the University of Southampton, explains how
nutritional supplementation in AMD management "means fewer people will therefore develop Wet AMD,
and reduce the need for treatment with expensive drugs."
Dry AMD, which is more common and tends to
precede wet, can be effectively treated with a
specific formulation of high dosage vitamins and
minerals, that ‘‘can slow down the condition by
around 25%. Hopefully this will stop people from
developing the severe forms.’’ This type of
prevention is therefore central in the
treatment of AMD.
The Age-Related Eye Disease Study (AREDS)†,
conducted by the National Eye Institute of
America over ten years, proved that a specific
formulation of high levels of Vitamins C and E,
beta carotene and zinc reduced the risk of
developing advanced AMD by 25%. The tablets
used in the AREDS study were supplied by
Bausch & Lomb and are currently available in the
UK market under the brand name PreserVision®.
It’s a point Professor Lotery is keen to reinforce:
‘‘In my practice I advocate the use of the AREDS
formula supplements as indicated by the study,
especially with vision loss in one eye.
This significantly reduces the risk of patients
progressing to the end stage of the disease.
It means fewer people will therefore develop
Wet AMD and reduce the need for treatment
with expensive drugs.”
AREDS formulation nutritional supplements
for AMD to reduce healthcare costs
Nutritional supplements could present real cost
savings for healthcare commissioners in the
treatment of patients with advanced AMD.
The AREDS study reported that 43% of patients
with ‘category 4’ AMD will lose their remaining
eye sight within five years, but that AREDS
formulation nutritional supplements would
reduce this risk by 25%.
Consequently, the use of nutritional supplements
could result in direct financial benefits in two
key areas:
• Direct eye health care costs - following the
NICE recommendations, the interventions with
anti-VEGF required in wet AMD cases will
grow by up to £12,000 per patient. Avoiding
this cost in 25% of cases would lead to a
direct saving equivalent to £135 per patient
using nutritional supplements per year.
• Other associated healthcare costs - the
evidence is now clear that vision loss is
associated with an increase in other
healthcare costs such as orthopaedic, A&E,
mental health, primary care. Together, these
conditions cost the NHS up to £1,000 every
year for each patient with vision loss.
Preventing these costs in 25% of cases gives a
direct saving of £75 per patient using
nutritional supplements per year.
With nutritional products costing around £120
per year, increasing the use of nutritional
supplements by high risk patients would
actually deliver a net reduction in overall
healthcare costs of about £90 per patient per
year. For an average PCT with around 400,000
patients, this could mean a saving of up to
£200,000 a year.
Professor Andrew Lotery spoke to the journalist
Clare Evans.
This article is credited with the permission of
Health Director/GovNet Communications.
Help Line: 01748 828781 PreserVision® Web site: www.preservision.co.uk
†A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and
vision loss: AREDS report no 8. Arch Ophthalmol 2001;119:1417-36 Age-Related Eye Disease Study Research Group
B+L Newsletter
26/3/08
11:07
Page 05
HEALTH
05
Bausch & Lomb’s
generosity is saving
sight in Africa
There are 37 million blind people in the world;
75% of all blindness can be treated or cured.
Leading global eye care company Bausch and
Lomb have donated over 9,500 intraocular
lenses (IOL's) to Sightsavers International to
support its work to prevent and cure blindness
in developing countries. Sightsavers carries
out an average of 238,514 cataract operations
annually and the IOLs will help to transform
the lives of those suffering from cataracts in
some of the poorest countries in Africa.
The lenses, with an estimated value of over
£200,000, will be used to perform life-changing
20 minute cataract operations restoring both sight
and independence to thousands of individuals.
Gareth Steer, General Manager of Bausch & Lomb
UK, highlighted the company's commitment:
"Bausch & Lomb UK decided last year to focus
its charitable support on a few reputable eye
related charities such as Sightsavers, British Blind
Sport, and Optometry Giving Sight. We believe
that the incredible difference these charities
make to people's lives is completely aligned to
our own mission of 'Perfecting Vision and
Enhancing Life', and we are proud to support
their wonderful work".
Phil Hoare, Procurement Manager for Sightsavers,
said: "Cataract is the biggest cause of blindness
in the world. For those suffering from cataracts in
the developing countries where we work, lack of
equipment for the operations can be a problem.
ZAMBIA
“This support from
Bausch and Lomb
will make a
difference by helping
us to fund even
more operations
this year.”
Phil Hoare, Sightsavers International
This support from Bausch and Lomb will make a
difference by helping us to fund even more
operations this year."
The first batch of lenses has already been sent
out to Sightsavers supported projects in Zambia,
and other orders will be dispatched to eye-care
projects in Uganda, Liberia, Nigeria and Cameroon
later this month.
The lenses will be used to help beneficiaries
like 72 year old Tabitha Charma from Mukumbo
in Zambia who was diagnosed and treated for
bi-lateral cataracts at the end of last year. When
she started losing her vision Tabitha had to stop
farming, losing the main source of income for her
and her seven grandchildren who live with her.
Tabitha heard about the possibility for treatment
through her church. After the operation, Tabitha
claimed she felt like she was in heaven as having
her sight back means she can move around her
village unassisted and go back to farming.
Sightsavers International is a registered UK charity (Registered charity numbers 207544 and SC038110) that
works in more than 30 developing countries to prevent blindness, restore sight and advocate for social inclusion
and equal rights for people who are blind and visually impaired. Since 1950, Sightsavers has restored sight to
more than 5.65 million people and treated over 100 million more. Donations to support Sightsavers' work can be
made using the 24-hour donation line 0800 089 2020 or via their website www.sightsavers.org
B+L Newsletter
26/3/08
11:07
Page 06
HEALTH
06
The truth about corneal staining
In recent years corneal staining and its relevance to eye health
has become a vision care industry wide discussion point. Bausch
& Lomb have developed an educational initiative to assist the
eye care practitioners in getting up-to-date information.
The evaluation criteria, clinical relevance
and causes of staining have been hotly
debated amongst researchers and
companies alike, with disparity originating
around these and the causes and effects of
corneal staining.
Corneal staining is a consequence of a natural
phenomenon which occurs through the
continual regeneration of old corneal cells for
new ones and therefore some degree of
corneal staining is expected in the general
population at any given time. Low level
corneal staining is commonly observed in
contact lens wearers during routine eye
examinations.
The application of topical dyes such as
sodium fluorescein is one of the most simple
and routinely used techniques used to
identify devitalised corneal cells.
Researchers have been using grading systems
to describe and quantify corneal staining over
many years, the world over. Although an
effective tool, it is important to remember
that these grading systems are intended to be
used in conjunction with professional
judgement and experience rather than as a
stand-alone clinical tool and are therefore
only as reliable and effective as the
practitioner is consistent.
Commonly used grading scales document the
extent and severity of corneal staining and
follow a global five step graded scale.
See figure 1 as an example:
Evidence suggests that staining is a prevalent
normal phenomenon in the general
population and a reflection of normal
epithelial physiology. There are two
independent epithelial cell functions that
naturally occur to maintain a healthy
epithelium.1
• Programmed cell death (apoptosis) is a normal important part of continual
turnover of corneal epithelial cells where
surface cells die
• Continuous regeneration - new cells are
generated from the underlying basal
layer through normal cell division and
complete the cycle
The application of topical dyes such as
sodium fluorescein is one of the most
simple and routinely used techniques
used to identify devitalised corneal cells.
GRADING SCALE
• Grade 0 = no staining, not clinically significant and no treatment required
• Grade 1 = trace staining, not clinically significant and no treatment required
• Grade 2 = mild staining, note in record and watch progression
• Grade 3 = moderate staining, therapeutic intervention recommended
• Grade 4 = severe staining, treatment required
Figure 1
B+L Newsletter
26/3/08
11:07
Page 07
HEALTH
07
“At Bausch & Lomb we are committed to delivering the best eye care science for our
customers. Through this corneal staining educational initiative our aim is to empower eye
care professionals with scientific fact and expert opinion.”
Esther da Silva, Vice President, Bausch & Lomb Vision Care, EMEA.
Clinical Management
The Implications
Educational Resources
With mild to moderate staining (grades 0, 1 or 2) no
action is generally required, but continued monitoring
is advisable.
Theories implicating corneal staining
(of any grade) as one of five contributory
factors to corneal infection (keratitis) has
been put into question by various
researchers and clinical studies.
Bausch & Lomb has launched the website
www.truthaboutstaininggrid.com; a corneal
staining educational website for eye care
professionals that reviews the science behind
existing and new methods of grading and evaluation.
The Institute for Eye Research showed that
419 contact lens wearers with corneal
inflammatory events showed no significant
difference in the degree of corneal staining
or predisposition to microbial keratitis
compared to the control group.4
This educational resource explores many aspects of
corneal staining including the natural phenomenon,
clinical relevance, classification methods and deeper
evaluation techniques as well as questionable
science. In addition, the site provides a valuable
resource of publications supporting many aspects of
corneal staining which are freely available to
download. A ‘contact us’ section invites comments
on corneal staining and feedback on the website.
More significant staining beyond the low grade
physiological levels may indicate a disrupted or
compromised corneal surface
as a result of one of six causes: mechanical, exposure,
metabolic, toxic, allergic and infectious. It is therefore
essential that eye care professionals prescribing
contact lenses recognise and understand the many
factors that can cause corneal staining.2
Clinically significant corneal staining is generally
asymptomatic and reversible with correct clinical
management and compliance.3
References:
1. Efron N. Grading Scales for contact lens complications. Appendix A. In: Contact lens Complications, Second Edition. Butterworth-Heinemann, Oxford 2004 pp. 239-243
2. Ward K. Superficial Punctate Fluorescein Staining of the Ocular Surface. Optometry and Vision Science; 2008; 85:1, 8-16
3. Snyder C. Solution Interaction with the Ocular Surface: The Significance in Making the Grade. Clinical & Refractive Optometry, 2005; 16:5, 134-140. Copyright Mediconcept 2005
4. Carnt NT et al. Corneal Staining: The IER Matrix Study. Contact Lens Spectrum, September 2007
B+L Newsletter
26/3/08
11:07
Page 08
SCIENCE AND TECHNOLOGY
08
An expert’s view
Mr Richard Packard, Consultant Ophthalmologist,
King Edward VII Hospital, Windsor, UK, talks about
his experiences of B-MICS and C-MICS with the
Stellaris™ system.
Interviewed by Lindsay Brooks, Medical Communication Manager, EMEA
Although it is early days since the European
launch, a number of surgeons have already
gained clinical experience with the Stellaris™
phaco system.
Mr Packard has already performed 50 cases
with the machine as part of the initial
European field observation studies on the
system. He discussed his experience in
performing both biaxial MICS and coaxial MICS
cases with the Stellaris™ system.
First, Mr Packard reviewed the reasons for
performing MICS:
• Less leakage when wounds properly formed,
leading to better surgical control with
advanced machine fluidics
• Minimal, if any, induced astigmatism
• Safer more rapidly healing wounds
• Faster rehabilitation for patients
• Patients can obtain their glasses earlier
And finally, because we can!
When considering whether to use the biaxial
or the coaxial approach, Mr Packard said both
techniques have their advantages and
disadvantages (figure 1).
How to be properly equipped for MICS?
Mr Packard then continued by summarising
the essential requirements for performing
MICS. Both the coaxial and biaxial techniques
require incisions and knives that match the
instrumentation, the irrigating chopper and the
phaco needle, whether sleeved or unsleeved.
Both techniques require micro surgical
capsulorhexis forceps and the surgeon needs
an understanding of hydro dissection with
micro incisions. The phaco system must
provide the appropriate power modulations,
and deliver excellent fluids with both
techniques, as smaller incisions make fluidics
delivery more difficult without reducing
phaco parameters.
A reduction in the incision size necessitates
coaxial sleeves which are thin but do not
compromise on the passage of fluid. The
biaxial MICS irrigating chopper must also
provide adequate flow. Surgeons must know
how to introduce the irrigating chopper and
bare phaco needle. Surgeons must also be
familiar with biaxial MICS cataract removal
techniques; usually the chopping technique.
The coaxial MICS technique does not require
a change in cataract removal techniques.
Good fluidics balance is necessary in both
techniques and the key here is to minimise
wound leakage. As less fluid goes into the eye,
it is important to minimise leakage, so in
C-MICS, Mr Packard advised to watch the side
port. He has designed a special chopper to fill
Advantages of Biaxial Micro Incisions
Advantages of Coaxial Micro Incisions
Improved tissue manipulation due to
separation of irrigation and aspiration
Sleeve protects wounds
Better visibility due to absence of sleeve
Fewer changes in technique and equipment
Ability to use new IOL technology
Ability to use new IOL technology
No astigmatism
Minimal astigmatism
Figure 1
B+L Newsletter
26/3/08
11:07
Page 09
SCIENCE AND TECHNOLOGY
the side port more fully. The power modulations
are intended to prevent temperature rise in the
phaco needle and also to reduce repulsion of
the nuclear fragments. Less leakage from the
eye and the generally lower fluidics parameters
used will reduce turbulence.
Mr Packard went on to show video footage of
a coaxial MICS case with the Vacuum Fluidics
Module (VFM). The vacuum setting was 425470mmHg and 20% power, with the pulsed
setting. He used the new 1.8mm C-MICS needle
to provide added resistance and thus maintain
chamber stability. The same settings and tip
were used for coaxial MICS with the Advanced
Flow Module (AFM), with a flow rate of 3035cc/minute. Both pumps were used with this
tip through a 1.8mm incision.
Mr Packard then showed a biaxial MICS case
with a 20G needle and the Advanced Flow
System, using a vacuum setting of 350400mmHg, again with 20% ultrasound power
in the pulsed mode. Even with this relatively
high vacuum setting for an unrestricted
needle, the chamber remained very stable.
The reason such low power settings could
be used even in dense cataracts was that
the new handpiece on the Stellaris™
generates a 25% longer stroke length. This
means that the power settings which would
have applied on the Millennium™ system are
no longer valid.
Mr Packard concluded by saying the
Stellaris™ system provides both biaxial
and coaxial possibilities for sub 2mm MICS,
now using either the vacuum or flow.
When accompanied by the Akreos™ MI-60
lens, MICS surgery, with the advantages
demonstrated above, becomes a reality
for most surgeons.
09
INDUCED ASTIGMATISM
FROM TEMPORAL WOUNDS
0.50
0.45
0.50
0.40
0.35
0.30
0.25
0.25
0.20
0.15
0.12
0.10
0.05
0.00
0
3.2mm 2.5mm 2.2mm 1.8mm
Figure 2
To find out more about the Stellaris™ Vision Enhancement System,
Bausch & Lomb UK, have the pleasure in announcing two MICS symposia
to be held in October 2008 which will be chaired by Mr Richard Packard.
Please see details below.
MICS Symposia
Tuesday 21st October 2008
Manchester, Art Gallery
Thursday 23rd October 2008
London, Dali White Room, County Hall
The scientific content will focus on the latest Micro Incision
Cataract Surgery techniques with key experts
sharing their experiences with you.
To register, or for further information,
please visit www.MICS-Symposium.com
or contact: Jill Collishaw, Marketing Manager - Surgical
E-mail: [email protected] Tel: +44 (0)7795 612501
B+L Newsletter
26/3/08
11:07
Page 10
SCIENCE AND TECHNOLOGY
10
Leading the way
10 Reasons why the Zyoptix® 217z100 is the market leading laser in Europe1
First laser with flying spot technology
This has allowed Bausch & Lomb to be
market leaders with many years of experience
and the largest installed base in Europe.
1
It is the only laser on the market that
incorporates a ‘homogeniser’
The homogeniser re-shapes the laser beam
profile to provide a laser spot that has the same
energy across the entire spot. This uniform
energy distribution allows sufficient energy for
cold ablation of stromal molecules. In turn, this
reduced heat delivery to the cornea, minimising
unwanted side effects e.g. swelling that can
affect predictability.
2
Unique ‘Truncated Gaussian Beam’ profile
This combines the best of the standard
Gaussian and flat top beams, and the truncated
beam profile is created by firing the homogenised
beam through 1mm or 2mm apertures of the
highly precise optical devise, the Zyoptix® card.
3
The Zyoptix® card delivers unique spot
architecture. The Truncated Gaussian beam
optimises overlap leaving a smooth
stromal surface (main
benefit from a Gaussian
beam) and uniform
energy delivering more
predictable results due to
less heat transmission
(main benefit of a flat top
beam profile).
The disadvantages of each
beam type are also
eliminated. The Guassian
beam does not have the
same energy throughout
the spot, and the flat top
beam is tissue hungry as
many overlapping spots are
required.
Temperature control unit
This ensures the correct
temperature for optimum gas usage
that regulates the beam homogeneity.
4
Highly sophisticated algorithms
Developed by world-class scientists
providing superior clinical outcomes.
5
Unique empirically calculated
combination of 1mm and 2mm spots
The exact ratio of 1mm and 2mm spots enables
a very fast treatment time. In fact, using the
1mm spot alone would have equated to a
treatment time of a 300 Hz laser. Benefits of
the 1mm and 2mm spots are:
6
a. No plume evacuator necessary
Plume evacuators are necessary in higher
frequency lasers to avoid interaction from the
new incoming laser shots with the plume of
the previous shot. Because the Zyoptix®
2mm beam is applied for the larger tissue
removal, a lower frequency is possible. In
addition, plume evacuators are noisy and
very often create sterility issues and impact
the predictability of the outcome.
b. Lower repetition rates
Smaller beams require a significantly higher
repetition rate for the same speed of
ablation. Higher repetition rates generate
mechanical stress on scanners, coated optics,
mirrors and other optical components. It is
not uncommon for high frequency lasers to
require more service visits and experience
more down time.
c. More precise eye-tracking
B+L Newsletter
26/3/08
11:07
Page 11
SCIENCE AND TECHNOLOGY
At 21.5cm the Zyoptix® 217z100 offers
one of the largest working distances
on the market
This large working distance offers obvious benefits:
7
a. Predictable outcomes
The large working distance facilitates a very
narrow angle at the point where the laser
beam targets the cornea. Differences and
changes to patient height therefore have
a limited impact on spot sizes. Inversely,
a small/low working distance results in a
wide angle for the incoming beam, and the
spot size changes exponentially if there are
even small variations to targeting height.
An unintended amount of energy is delivered
to the cornea resulting in over and under
corrections, unpredictable results and
complicated nomograms to adjust for the
variations.
b. Low decentration rate
Small/low working distances are a cause for
frequent decentrations, resulting in a higher
re-treatment rate.
c. Epi-LASIK friendly
With the rising popularity of surface ablation,
and Epi-LASIK in particular, a larger working
distance makes life considerably easier for
surgeons and staff.
d. General ergonomics
A large working distance allows for easy
access for patient, nurse and surgeon pre
and post treatment. Some patients also suffer
from claustrophobia, and a larger working
distance offers a psychological benefit.
Advanced eyetracking technology
Bausch & Lomb is currently trialing its latest
eyetracker. The Advanced Control Eyetracker offers
the following benefits:
8
a. Active and passive X and Y tracking
This includes a controlled feedback loop and a
dynamic component that forces the laser to
cease firing should the eye move out of range.
b. Passive Z tracker
This ensures that the patient/eye height is
always within acceptable target ranges.
c. Dynamic rotational tracking
During treatment and static rotational
tracking prior to treatment to align ocular
rotation to match the diagnostic imaging.
High quality illumination systems
Infrared illumination from the goose necks
contribute to a very stable eyetracking system.
All other illuminations (cold light LED and
9
11
SELECTING A SURGEON
Selecting a refractive surgeon may be the most important decision of all and
should be done only after careful consideration. Bausch & Lomb can help you
find a qualified laser surgeon in your area.
Qualities that contribute significantly to an ideal surgeon:
• Years of experience performing LASIK procedures
• Uses the most advanced technology available in order to provide safe,
personalised treatment with excellent results
• Surgeon and staff who understand this is a major decision and can confidently,
simply and clearly present personalised options that give you complete comfort
and confidence in the decision you make
• You should ask your surgeon any questions you feel are necessary to help you
assess his or her qualifications and make sure that you are satisfied before
undergoing surgery. Only you can make this important decision.
To make a selection use the following website link:
http://www.bausch.co.uk/en_UK/consumer/surgical/findsurgeon.aspx
infrared illumination for iris recognition) are
incorporated into the laser. Therefore, there
are no external moving mechanical parts that
interfere with surgery or create sterility problems.
Advanced personalised technologies
Surgeons that acquired Zyoptix®
technology when it was first launched will
remember the 2 hour duration for a patient to
complete the diagnostics phase. This was
largely due to the requirement of undilated
and dilated Zywave measurements.
10
In 2006, Advanced Personalised Technologies
were launched to improve the diagnostic cycle.
Surgeons noticed a dramatic improvement, and
it is now possible for the majority of patients to
complete a full cycle and access the treatment
file on the laser in 6 mins. Advanced Personalised
Technologies include:
a. Advanced Nomogram
This Nomogram is calculated on an individual
treatment basis, and considers the interactions
between the lower and higher order aberrations.
Surgeons using the Advanced Nomogram
typically have a retreatment rate of less than
1%, and 72% of treatments are within ±0.25 D
UCVA of the intended treatment.
b. NoDiZy (No Dilation Zyoptix®)
The NoDiZy algorithm extrapolates about 10%
of a Wavefront, allowing for about 70% of
patients not to undergo pharmacological
dilation, dramatically reducing the diagnostic
work up time.
c. TruLINK connectivity solution
TruLINK eliminates the need for saving
and transporting patient file data on a floppy
disk. TruLINK connects the diagnostic
equipment, a remote treatment calculator PC
and the laser to each other to dramatically
speed up the treatment process. It also
allows, if so wished, for Bausch & Lomb to
remotely monitor the status of the clinic
equipment through a secure Internet
connection, and detect problems before they
impact the clinic. TruLINK therefore provides
a 24 hour preventative maintenance service
and minimises downtime.
A fully committed Bausch & Lomb Research and
Development team is currently developing new
generation algorithms, diagnostic and laser
systems. Advanced TruLINK applications will
enable remote training support and desktop
sharing in the future. Zyoptix® XP Epi-Separator
system will be available soon to capitalise on
the growing surface ablation market.
Bausch & Lomb continues to provide products
that deliver superior clinical results. Our
philosophy is to focus on what technology is
best for the patient. Therefore, Bausch & Lomb
will continue to be market leader in Europe and
be the best partner for any refractive surgeon.
Reference
1
TforG Independent Market research, 2005
B+L Newsletter
26/3/08
11:07
Page 12
SCIENCE AND TECHNOLOGY
12
Upgrade your patients to High Definition Vision
PROPERTIES
BENEFITS
Decreased Lens Mass
Increased Comfort
Increased Oxygen
Transmission
Increased Material
Tear Strength
Decreased Damage
During Handling
Added Poloxamine
Packaging Solution
Increased Comfort
Added Aspheric Optics
Decreased Spherical
Aberration
Increased Vision
Increased Peripheral
Vision
Figure 1. SofLens® daily disposable contact lens properties
Recent studies that address complications of
contact lens wear have highlighted a number
of items that can be used to screen or advise
current and prospective wearers e.g. living far
from an ophthalmic or medical practitioner,
swimming, smoking etc. Knowledge of these
factors will contribute to successful contact lens
practice. Of significant interest is the fact that
daily disposable contact lenses were not
associated with any increase in risk of
infiltrative events or severe keratitis, perhaps
displaying the robustness of the modality to
withstand factors of non-compliance.
Given that there are years of clinical experience
to support the health attributes of daily
disposable contact lenses, practitioners can
confidently prescribe these lenses with peace of
mind. Health is important and many patients do
take an interest in the health of their eyes but
it is the every-day aspects of contact lens wear
that may determine ultimate success. For the
daily disposable contact lens modality there are
three main aspects of lens wear that drive
patients opinion and acceptance: Comfort,
Vision and Handling. It is important that all of
these be specifically addressed in the product
design to meet patient expectations.
The new SofLens® daily disposable contact lens,
recently launched in the UK by Bausch & Lomb,
has been designed on the basis of these three
factors. This lens has been made using an
advanced hydrophilic polymer, hilafilcon B.
The non-ionic properties of this material provide
resistance to build up from tear debris thus
providing and maintaining a clean lens surface
throughout the day. The lens design has been
significantly modified from its predecessor,
SofLens® One Day. The overall reduced lens mass
is specifically designed to enhance comfort
without compromising handling attributes. A
further advantage of a reduced mass lens is
improved oxygen transmissibility.
It is important to note that the reduced thickness
does not indicate a reduction in integrity, as the
improved tensile properties of the hilafilcon B
material increases tear strength to reduce the
incidence of lens damage while handling (figure
1). Additionally, the lens has been packaged with
a solution containing Poloxamine which acts as a
conditioning agent that attracts moisture to
maintain wearing comfort.
Advances in contact lens design, established
by Bausch & Lomb, has made it possible to
introduce aspheric optics into SofLens® daily
disposable contact lenses. This is an important
step as the population average spherical
aberration has been reported to be of the order of
+0.15µm, an amount capable of reducing retinal
image quality. Correcting this aberration is
complicated by the fact that the standard spherical
optics of contact lenses actually induces an
amount of spherical aberration which varies with
the power of the lens (figure 2).
The anterior optic zone of the SofLens® daily
disposable lenses has been designed to adjust the
amount of asphericity for each power of contact
lens and reduces the population average spherical
aberration. When the spherical aberration is
reduced, more light reaching the retina is focused
at exactly the same point, which enables better
resolution. A clinical study of 40 subjects
demonstrated that the aspheric optics can provide
a significant reduction in spherical aberration
when compared to the AcuVue 1-Day lens (figure
3). There remain aspects of this lens design which
have yet to be fully explored. A recent study
examining peripheral visual acuity demonstrated
the aspheric optics of SofLens® daily disposable to
provide a larger field of clear vision when
compared to Acuvue® 1-day and Focus Dailies®.
A feature which could be of tremendous utility in
driving or sports.
With design elements targeting the three key
features, Comfort, Vision and Handling, clinical
evaluation was performed assessing their
influence on the lens wearing experience. Several
large multicentre clinical studies have been
conducted to test not only the safety of the
lenses, but the efficacy in meeting the rigorous
demands of patient satisfaction. The first study
compared the SofLens® daily disposable (Test)
to its predecessor the SofLens® One Day (Control).
This study was a randomised, crossover study
where the 75 subjects who completed the study
wore either the Test or Control Lens lenses
(-0.25D to -6.00D) for four weeks on a daily
disposable schedule. At the end of four weeks,
the subjects were examined and rated the lens on
a variety of performance related measures, then
subjects were dispensed the other lens to wear
for four weeks again on a daily disposable basis.
At the end of the study, subjects were examined,
rated the lens and answered a forced choice
preference questionnaire.
LEVEL OF POPULATION AVERAGE
POSITIVE SPHERICAL ABERRATION
-7.00D -6.00D -5.00D -4.00D -3.00D -2.00D -1.00D
LEVEL OF SPHERICAL ABERRATION
OF CONTACT LENS WITH
SPHERICAL SURFACES
SF>1
SF<1
LEVEL OF SPHERICAL ABERRATION TO
THEORETICALLY OFFSET POPULATION AVERAGE
(ASSUMING PERFECT LENS CENTRATION)
+0.10µm
SPHERICAL
ABERRATION
A recent survey has shown that daily disposable
contact lenses account for approximately one
third of all contact lens fits and re-fits in the
UK. This important modality has many benefits
which are of value to the contact lens patient.
Disposing of the lens at the end of the day and
opening a new sterile contact lens every
morning enhances hygienic practices and
reduces compliance issues associated with lens
care. Indeed, practitioners may feel compelled
to prescribe a daily disposable modality
on this basis alone.
0
POWER
+0.20µm
-0.10µm
-0.20µm
Figure 2.
Graph depicting the
population average
spherical aberration
and the level of
spherical aberration
induced by varying
powers of contact
lenses with spherical
surfaces.
11:07
Page 13
SCIENCE AND TECHNOLOGY
A second study, almost identical to this first study,
was conducted, this time employing 106
SofLens®
daily disposable
(Occurrence Rate %)
SofLens®
one day
(Occurrence Rate %)
Epithelial Edema
0.0
0.0
Epithelial Microcysts
1.3
0.0
Corneal Staining
0.0
1.3
Limbal Injection
0.0
0.0
Bulbar Injection
0.0
0.0
Sup. Tarsal Conjunctival
Abnormalities
0.0
0.0
Corneal Neovascularization
0.0
0.0
Corneal Infiltrates
0.0
0.0
Figure 4. Grade 2 or above Slit Lamp Findings in a 1 months study of SofLens® daily disposable compared to SofLens® one day
92 93 91*
89*
83* 83*
93 92
87*
84*
74*
73*
Redness
100
95
90
85
80
75
70
65
60
55
50
Absence
of Dryness
Figure 5. Results from subjective ratings of various
performance attributes of SofLens® daily disposable and the
Control lens. (Subjects were asked to rate these measures
on a scale from 0 to 100, where 0 = the least favourable
response and 100 = the most favourable response).
80
70
60
50
40
30
20
10
0
FORCED CHOICE PREFERENCE
*
* Statistically significant (p<0.05)
With these large multicentre clinical trials it
has become evident that the design attributes of
the SofLens® daily disposable have indeed created
significant improvements in daily disposable contact
lens performance and meet the high demands of
contact lens wearers. Further assessment of the
performance capabilities have been conducted
against Focus Dailies disposable lenses. In a one
week trial of SofLens® daily disposable on 100
subjects who routinely wore Focus Dailies®, there
were many similarities. Attributes such as
centration and movement were not different
(p>0.05 in all cases) again suggesting an easy refit
into the SofLens® daily disposable. Even when
rating comfort throughout the day there was again
no difference determined (p>0.05). However, for
For a full list of references please e-mail [email protected].
The full article first appeared in Optician 2.11.07, pages 14-16.
Irritation
hyperopic subjects (212 eyes; +0.25D to +6.00D)
and conducted over a two week crossover period.
Interestingly, the results mirrored the first study as
again there was no difference in slit lamp findings,
centration, movement and sphere power between
the SofLens® daily disposable and SofLens® One
Day. Additionally, when rating the various
attributes of lens performance SofLens® daily
disposable performed significantly better for most
attributes and again End of Day Comfort and
Dryness were rated 9 points higher than the
control lens. Forced choice data showed the same
trend with a two-to-one preference for the
SofLens® daily disposable on comfort and
handling attributes; vision achieving nearly a
three-to-one preference.
The new SofLens® daily disposable contact lens is
a valuable tool for the contact lens practitioner.
Clinically, there is strong evidence for practitioners
to seriously consider adopting this lens as a first
choice for daily disposable wear.
Burn/
Sting
Throughout the study there were no adverse
events and slit lamp findings showed almost no
grade 2 or above findings for either lens
demonstrating, not only statistical equivalence, but
the safety of both contact lenses (figure 4). In the
assessment of lens fit, there was no statistically
significant difference in lens centration or
movement and the prescribed sphere power was
the same for both lenses in all patients (100%)
who completed the study.
All of these are important considerations when refitting existing SofLens® One Day patients into the
new SofLens® daily disposable. Subjects were
asked to rate various attributes on a scale from 0
to 100 where 0 represents the least favourable
response and 100 represents the most favourable
response (figure 5). The results reveal that the
SofLens® daily disposable performed significantly
better, particularly for End of Day Comfort and
Dryness where the difference in scores was 10
and 9 respectively. (A difference of 5 is generally
regarded as being clinically significant in that a
patient is likely to appreciate the difference.)
Furthermore, Handling and Overall performance
demonstrated significant advantage for the
SofLens® daily disposable. The forced choice
questionnaire again revealed the SofLens® daily
disposable to be preferred over the control for
comfort, vision and handling attributes by
approximately two-to-one (figure 6).
1.0
EOD
Comfort
0.5
*
*
SofLens®
One Day
0.0
End of Day
Comfort
Overall
Vision
Insert &
Remove
Figure 6. Results from the forced choice preference
questionnaire indicating significant preference for
the SofLens® daily disposable.
100
90
80
70
60
50
40
30
20
10
0
SYMPTONS/COMPLAINTS
86
87
79*
86*
74*
81*
Focus Dailies®
-0.5
Residual + 0.11µm
SofLens® daily disposable
SofLens® One Day
microns of
-1.0
spherical aberration
ACUVUE® 1 DAY
Comfort
Residual + 0.00µm
SofLens® daily disposable
0
POWER
SofLens® daily disposable
-7.00D -6.00D -5.00D -4.00D -3.00D -2.00D -1.00D
Subjective Response (0-100)
Residual + 0.04µm
ratings of End of Day Comfort and Dryness, there
was a statistically and clinically significant
difference in favour of the SofLens® daily
disposable (p<0.05) (figure 7). The results would
indicate that End of Day Comfort and Absence of
Dryness are distinguishing features of this new lens.
The aspheric optics designed into the lens has not
only demonstrated reduction of spherical
aberration, but excellent visual quality. Lastly,
through innovative lens and packaging design, the
handling performance of this lens would appear to
be highly rated by contact lens wearers.
Percentage (%)
Residual + 0.01µm
Figure 3. Forty subjects participated in
an evaluation of spherical aberration
with SofLens daily disposable contact
lenses. Subjects were dilated to achieve
a minimum of 6 mm pupil diameter.
Baseline spherical aberration was
measured using a Zywave™ aberrometer.
SofLens® daily disposable contact lenses
and AcuVue 1-day contact lenses (-1.00D
and -5.00D) were inserted, and the
measurement of spherical aberration
was repeated. Wavefront aberration
maps and simulated retinal images were
generated using Vision Optics Laboratory
software. The letter represents a 20/80
letter size viewed through a 6 mm pupil
and an eye with no other aberration
except for spherical aberration.
Subjective Response (0-100)
SOFLENS® DAILY DISPOSABLE
13
* Statistically significant (p<0.05)
26/3/08
Comfort
EoD Comfort
Absence of
Dryness
Figure 7. Subjective ratings of comfort related parameters
demonstrating better performance with the SofLens®
daily disposable lens.
* Statistically significant (p<0.05)
B+L Newsletter
B+L Newsletter
26/3/08
11:07
Page 14
EDUCATION
14
European Refractive Centre of
Excellence Training Courses 2008
The Centre of Excellence is also the location of
our prestigious Training Centre. The training
facilities have been specially designed for easy
demonstration of our products. You will be able
to enjoy hands-on experience as well as
understanding the technical aspects of our
technology platform.
The Bausch & Lomb Centre of Excellence is
located about 20 minutes drive from the
centre of Munich, Germany.
It is home to our Global Refractive Research
and Development, Technical Service, Global
Application Training, Manufacturing and
Customer Service departments.
When attending one of our courses, you will
have the opportunity to join a company tour to
see where our lasers and diagnostic equipment
are manufactured. Lastly, and if time allows, a
tour of Munich will be arranged to ensure that
you also enjoy the beautiful sights of this
charming city.
To attend any of the following courses,
or for further information, please contact:
Asa Baudin
E-mail: [email protected]
Tel +44 (0)20 8781 0000
MUNICH
COURSE: TECHNOLOGY FOR THE FUTURE
Find out how Bausch & Lomb can provide a market leading refractive platform for your clinic.
Suitable for
• Customers unfamiliar with the Bausch
& Lomb Zyoptix® Platform
• Surgeons completely new to refractive
surgery*
• Marketing support you can expect at
Bausch & Lomb
• A brief overview of products for the
future
• A tour of our manufacturing plant
• A tour of Munich, if time allows
Content
• Introduction into Refractive Technology
and Science
• Overview of the Zyoptix® Platform
including basic principles of our
diagnostic instruments, laser and
keratome
• Clinical results you can expect using
our platform
• Practical hands-on session on the
entire platform
• A brief overview of the competitive
landscape
Knowledge and skills gained
After you have attended this course, you
will know:
• Why the Zyoptix® Platform is suitable for
your clinic
• What ‘After Sales’ support you can expect
• Why Bausch & Lomb's future products
meet your needs
• Why you want to build a long term
relationship with Bausch & Lomb
Cost
660 euros per person (excluding flights
and hotel) includes dinner, lunches,
course materials and Munich tour if
time allows.
Course dates (arrival recommended
day before course or two days for
surgeons new to refractive surgery*)
19 - 20 May 2008
7 - 8 July 2008
17 - 18 November 2008
* For these surgeons, an additional
training day will be offered preceding
this course. Basic principles of optics
will be covered in this bespoke course.
B+L Newsletter
26/3/08
11:07
Page 15
EDUCATION
15
COURSE: ADVANCED NURSE AND TECHNICIAN
Improving skills of your support staff enables easier, quicker and safer treatments.
Suitable for
Technicians, Nurses, Theatre Staff,
Optometrists with at least 1 year's
experience using the Zyoptix®
diagnostic equipment and/or keratome.
Content
• Introduction into basic principles of
refractive surgery including optics and
treatment options
• Brief overview of the features and
benefits of Advanced Personalised
Technologies
• Intensive hands-on session detailing
tips and tricks to obtain the most
accurate diagnostic readings, do
excellent fluence tests on the laser
• Keratome handling and sterilisation
• Patient flow optimisation
• Data storing and database management
• Communication with a patient and
using the right language
• A tour of our manufacturing plant
• A tour of Munich, if time allows
Knowledge and skills gained
• Be able to better distinguish a good
diagnostic map from a poor map
• Be able to position patient best to obtain
better acquisition, leading to better
outcomes
• Be able to manage diagnostics in
complicated cases e.g. re-treatments
• Able to advise on how best to manage
patients and their records in your clinic
• Extend the life of your keratome by
implementing better care methods
• Maximise the support this person can
bring to you in your clinic
Cost
330 euros per person (excluding flights
and hotel) includes dinner, lunches, course
materials and Munich tour if time allows.
Course dates (arrival recommended
day before course)
Dates for this course have been
carefully selected to take place in
quieter times of the year, or when a
surgeon is most likely to attend an
International convention.
21 - 22 July
18 - 19 August
29 - 30 September*
* This is during the Oktoberfest, and
dinner will be enjoyed at one of the
world famous Beer tents. As this is a
very popular time, please reserve
your place well ahead as spaces are
limited, and also consider limited
flight availability.
COURSE: ZYOPTIX® INNOVATIONS
How to significantly improve your clinical results, clinic flow and patient satisfaction.
Suitable for
Existing Bausch & Lomb customers
seeking more information about latest
Bausch & Lomb innovations that will
improve clinical results and enhance
patient flow.
• In-depth review of our Research and
Development programmes - meet the
researchers in person
• A tour of our manufacturing plant
• A tour of Munich, if time allows
Knowledge and skills gained
Content
• History of Zyoptix®
• Advanced Personalised Technologies
(APT) for improvement of diagnostic
instruments Advanced Control
EyeTracking™ Technologies (ACE)
for state-of-the-art eyetracking
• Practical hands-on session using the
new technologies (APT and ACE)
• In-depth overview of the competitive
Landscape Clinical data of our new
technologies
After you have attended this course, you will:
• Know why you would like to upgrade
your system with the B&L new
technologies
• Understand what competitors have to
offer in relation to the Zyoptix® Platform
• Know why Bausch & Lomb's future
products meet your needs
• Understand the full support Bausch &
Lomb offers should you wish to upgrade
your system
Cost
660 euros per person (excluding flights
and hotel) includes dinner, lunches, course
materials and Munich tour if time allows.
Course dates (arrival recommended
day before course)
28 - 29 April 2008
1 - 2 October 2008*
* This is during the Oktoberfest, and
dinner will be enjoyed at one of the
world famous Beer tents. As this is
a very popular time, please reserve
your place well ahead as spaces are
limited, and also consider limited
flight availability
B+L Newsletter
26/3/08
11:07
Page 16
EDUCATION
16
Lecture Series launch the new
Bausch & Lomb Academy of Vision Care™
More than a thousand eye care professionals from around the UK flocked
to the Bausch & Lomb lectures in March 2008.
by 23% – meaning that many contact lens
wearers will become presbyopic and expect to
continue wearing lenses that provide comfort
and vision. Caroline said that eye care
professionals needed to consider the latest
generation of lens designs for the over 50s.
Jonathan Walker, Contact Lens Practice Walsall,
spoke about adverse events and gave advice on
when to be concerned and when to monitor.
While Dr Philip Morgan, Director of Eurolens
Research, spoke about what advice eye care
professionals could give to customers to reduce
their risk of keratitis. ‘It is known, for example,
that smoking increases the risk of keratitis as
do not using the correct storage solution, not
rubbing and rinsing lenses, not handwashing or
sleeping in unsuitable lenses,’ he said. These
characteristics were identified by B&L’s Science
of Compliance study which examined the
behaviour of 1400 contact lens wearers.
The series of one-day events in London,
Cardiff, Coventry, Manchester and Glasgow
marked the launch of Bausch & Lomb’s
Academy of Vision Care™.
Opening the lecture series in London, Cheryl
Donnelly, Director of Professional Services and
Clinical Affairs, B&L UK said “These lectures are
the first of many educational initiatives for the
Bausch & Lomb Academy of Vision Care™.
The lectures have been developed through
consultation with key opinion leaders to
communicate some of the latest issues in
contact lens practice”.
Among the speakers was Caroline Christie,
Associate Director Contact Lenses at City
University, who argued that age should not be
a barrier to contact lens wear. By 2020 the
number of people over 50 will have increased
William Harvey, Clinical Editor, Optician, stressed
the importance of diet as well as smoking on eye
health – particularly relating to AMD progression and encouraged eye care professionals to
consider offering nutritional supplement advice
where appropriate. Shehzad Naroo, lecturer at
Aston University, introduced the audience to
newer lens surface properties in spherical, toric
and multifocal contact lenses designs. The future
provided an opportunity to achieve optimum
vision for all contact lens patients, he said.
To finish the day, Dr Gary Osborn, Director of
Medical Marketing, Global Vision Care Strategy B&L
tackled myths about lens care head on.
Specifically they spoke about superficial, transient
“These lectures
are the first of
many educational
initiatives for the
Bausch & Lomb
Academy of
Vision Care™”
Cheryl Donnelly,
Director of Professional Services
and Clinical Affairs
corneal staining which can occur in both lens and
non-lens wearers, at a higher or lower rate
depending on ocular condition and various
solution/lens combinations. Based on the scientific
data they argued that there is no evidence to
suggest that this level of corneal staining
increases risk for contact lens-related corneal
infection.
Mike Evans, Commercial Director for B&L UK,
said more Bausch & Lomb Academy of Vision
Care™ events would follow and encouraged eye
care professionals to feed ideas in by email to
[email protected]. ‘This initiative will
ensure that our customers are at the forefront
of technological and scientific breakthroughs,
and are provided with practical experience
based learning opportunities and knowledge
resources that address their day-to-day practice
and business challenges,’ he said.
B+L Newsletter
26/3/08
11:07
Page 17
EDUCATION
17
Up-coming Congress
Bausch & Lomb UK have the pleasure to be the sole sponsor
for the 62nd Detachment teaching course on Vitreo Retinal
surgery organised by renowned vitreoretinal surgeon
Professor Ingrid Kreissig and featuring an international faculty
of speakers. This course carries 14 CPD points.
CONGRESS DATES 2008
April 4 – 9, 2008
ASCRS
Chicago, USA
April 27 – May 1, 2008
ARVO
Florida, USA
May 9, 2008
May 20 – 22, 2008
RCO
Liverpool, UK
May 29 – June 1, 2008
BCLA
Metropole Hotel, Birmingham, UK
June 20, 2008
VIIIth State of the Art Refractive
& Cataract Surgery Symposium
Hull, UK
July 5 – 6, 2008
BSRS
Oxford, UK
Birmingham UK, 5-6 June 2008 at the International Convention
Centre (following the joint meeting of the Midland and Northern
Ophthalmological Society held in Sheffield, 4 June 2008)
Topics
• Diagnostics - The Fellow Eye
• Cerclage, Segmental Buckling
(Sponge, Balloon)
• Gas Operations - Vitrectomy
• Uveitis - Age-Related Macular
Degeneration
• Re-operation - Ocular Trauma
• Comparison of present surgical
techniques
• The Diabetic Eye
• Panel discussion with case
presentations
Programme
Prof. Dr. med. Ingrid Kreissig,
Augenklinik, Univ. Mannheim-Heidelberg,
Theodor-Kutzer-Ufer 1-3,
68167 Mannheim, Germany
Website: http://kreissig.uni-hd.de
E-mail: [email protected]
Local Organisation
Mr Robert AH Scott,
Vitreoretinal Surgeon,
Dept. of Ophthalmology, Selly Oak Hospital,
Raddlebarn Road, Birmingham, UK B29 6JD
Tel : +44 (0)121 627 8351
Fax : +44 (0)121 627 8922
E-mail: [email protected]
July 7 – 9, 2008
Oxford Congress
Randolph Hotel, Oxford, UK
September 13 – 17, 2008
XXVI ESCRS Congress
Berlin, GERMANY
September 19 – 21, 2008
ABDO Conference
Mercure Holland House Hotel
Cardiff, UK
November 8 – 11, 2008
AAO
Atlanta, USA
November 13 – 14, 2008
UKISCRS
Brighton, UK
November 27 – 28, 2008
BEAVRS Meeting
Reading, UK
December 8 – 9, 2008
Moorfields Ophthalmology Course
for General Practitioners
Institute of Child Health, London, UK
B+L Newsletter
26/3/08
11:07
Page 18
BAUSCH & LOMB IN FOCUS
18
Introducing customer services
Education is a key theme for Bausch & Lomb in 2008 and nowhere is
this more important than with our dedicated customer services teams.
All of the 40 members of the three teams
attend the Bausch & Lomb University where
they can take modules from over 1000
courses for their own personal development.
They also attend the Bausch & Lomb training
school on a regular basis where they receive
training from experts on the company’s full
product portfolio. With a focus on recruiting,
developing and retaining talented people, and
by investing in training and development,
Bausch & Lomb aims to lead the industry in
customer focus.
We have recently introduced online ordering for
refractive, pharmaceutical and the vision care
product ranges. Electronic ordering (EDI) is also
available for all products providing you with an
electronic invoice. Alternatively, you can contact
our customer services team directly by phone or
fax on the numbers listed below where our
upgraded telecoms system will present you with
a dedicated customer services representative
and your account details.
All of the teams are UK are based at our newly
refurbished Kingston-upon-Thames offices.
Melanie Short, Senior Business Administrator, Surgical Division
Within this team there are 5 people dedicated
to service and installation, who monitor and
manage the time of our 5 engineers and can
deal with specific issues such as contracts,
warranty and spare parts.
General Tel: 020 8781 0000
Service Team: 020 8781 2843
Fax: 020 8781 0001
Pharmaceutical Team
Contact our small but dedicated Pharmaceutical
team who can offer refrigerated delivery to a
specific point in the hospital, lines are open
Monday to Friday from 8.00am – 4.00pm.
The pharmaceuticals team can track your order for
you and provide proof of delivery if required. The
team also has a dedicated returns department.
Tel: 020 8781 0000 Fax: 020 8781 0001
Surgical Team
The Surgical team covers the varying needs of
cataract, vitro retinal and refractive businesses.
In this department each customer has their own
dedicated customer services representative; lines
are open from Monday to Friday from 8.00am –
5.30pm. Our Refractive customers can also order
their consumables online. The Surgical team can
track your order for you and provide proof of
delivery if required. This team also benefits from
a dedicated returns department.
Vision Care Team
Vision Care Customer Service is open 6 days a
week to meet the needs of the optical industry.
Lines are open Monday to Friday from 9.00am –
5.30pm and 9.00am – 2.00pm on Saturday.
The dedicated Vision Care team is committed to
providing customers with a ‘one stop shop’
offering a free delivery for orders placed on line,
a flexible returns policy and a comprehensive
service recovery programme.
Tel: 0845 6022350 Fax: 0845 6022351
FIND OUT MORE...
For further information on Bausch & Lomb
and its products please visit the website at
www.bauschonline.com
B+L Newsletter
26/3/08
11:07
Page 19
For all your eye care needs....
Contact Lenses
Lens Care
Laser Eye Correction
Dry Eye Relief
Eye Health Supplements
Cataract
Pharmaceuticals
Vitreo Retinal
Ophthalmic Instruments
....your Trusted Partner in Eye Health
www.bausch.co.uk
B+L Newsletter
26/3/08
11:07
Page 1000
Coming up in the summer issue...
B & L's vision aids 'British Blind Sport'
Consumers getting worse at compliance
Celebration - a decade of the Akreos IOL
If you have any comments on this magazine, or would like to contribute to the
next issue, then please contact the Editor, Jill Collishaw: [email protected]
www.bausch.co.uk
™ and ® denotes trademark and registration mark of Bausch & Lomb Incorporated.
© Copyright 2008 Bausch & Lomb Incorporated. All rights reserved.
BLNLS-1/2007 Date of preparation March 2008
Bausch & Lomb Incorporated
Bausch & Lomb House
106 London Road
Kingston-upon-Thames
Surrey, KT2 6TN, UK
Tel:
020 8781 2900
Fax:
020 8781 2901
Website: www.bausch.co.uk